Ranbaxy & Lilly: Flexibility in Building a Generics Business
Through Ranbaxy, the joint venture can provide its own raw materials and access highly efficient, low-cost manufacturing and development operations. Lilly contributes sales, marketing and regulatory know-how in the US and other Western markets.
You may also be interested in...
Sandoz, the generics unit of Novartis, is buying Sabex, a Canadian maker of injectable generics for $565 million cash, marking its entree into an attractive sector of generics and also the Canadian generics market. The 6X sales multiple aimed to dissuade Sabex owners from shopping for another buyer. Novartis is the only big pharma company to succeed in generics. Its play is opportunistic, but a secondary effect is a free-market response to pressure on big pharma to make drugs more affordable.
Generic firms are attacking drug patents--even before they expire--with increasingly clever legal strategies. And it looks like the FDA may be helping them do it.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.